Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

James M. Apgar, Robert R. Wilkening, Dann L. Parker, Dongfang Meng, Kenneth J. Wildonger, Donald M. Sperbeck, Mark L. Greenlee, James M. Balkovec, Amy Flattery, George K. Abruzzo, Andrew Galgoci, R.A. Giacobbe, Charles Gill, Ming‐Jo Hsu, Paul Liberator, Andrew S. Misura, Mary Motyl, Jennifer Nielsen Kahn, Maryann Powles, Fred Racine, Jasminka Dragovic, Weiming Fan, Robin Kirwan, Shu Lee, Hao Liu, Ahmed Mamai, Kingsley H. Nelson, Michael Peel